Get the scoop on our progress and newsworthy events.
Dominique Demolle, CEO of Cognivia, is set to deliver a captivating presentation at the upcoming DPharm conference which is scheduled for…
What the FDA’s Final Guidance on Covariates Means for Fighting the Placebo Response in RCTs: Our Article Published in ACRP Journal
The recently released final guidance by the U.S. Food & Drug Administration (FDA) on “Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products” introduces a new framework that is poised to transform the way statistical analyses are conducted in RCTs.
Covariate Adjustment in Randomized Clinical Trials Based on Latest FDA Guidance: Application to composite covariates
In May 2023, the FDA has unveiled its definitive guidance titled “Adjusting for Covariates in Randomized Clinical Trials (RCT) for Drugs…
Patient adherence remains a significant challenge in clinical research and medical practice, affecting drug development, healthcare costs, and…
The next frontier in clinical research & patient management
We’re proud to be leading the charge into the next era of drug development.
Cognivia helps clinical trials reduce data variability, empower decision-making, and accelerate the launch of new therapies.
Tell us about your clinical trial below and we’ll be in touch.
"*" indicates required fields